Your Health, We Care
Release date: 2026-02-13 17:18:13 Recommended: 13
Eltrombopag is an oral thrombopoietin receptor agonist that provides an effective treatment option for thrombocytopenia caused by various reasons.
Eltrombopag (brand name: Revolade®) was officially launched in China in 2017 and has been successfully included in the national medical insurance catalog, significantly improving patient access to the medication. In addition to the original eltrombopag, various generic versions are available on the market. Patients can obtain this drug through regular hospitals, authorized pharmacies, compliant online platforms, and professional medical institutions.
Main Indications
Chronic immune thrombocytopenia
(1) Suitable for adult and pediatric patients who have had an insufficient response to conventional treatments such as corticosteroids and immunoglobulins.
(2) Patients who relapse after splenectomy and require treatment.
Applicable age: Patients aged 1 year and older (dosage varies by age group).
Extended Indications
Thrombocytopenia associated with chronic hepatitis C
Used to increase platelet counts to enable the initiation and maintenance of interferon antiviral therapy.
Eltrombopag should be discontinued after antiviral treatment ends.
(1) Target platelet count: Maintain at ≥50×10⁹/L; normalization should not be pursued.
(2) Minimum effective dose: Use the lowest dose that achieves the target platelet count.
(3) Maximum dose limit: Do not exceed 75 mg daily for ITP patients and 100 mg daily for hepatitis C patients.
Immune thrombocytopenia
(1) Standard adults and children over 6 years: 50 mg once daily.
(2) Patients with hepatic impairment: 25 mg once daily.
(3) Children aged 1-5 years: 25 mg once daily.
Proper Administration Method
(1) Timing: Take on an empty stomach, either 1 hour before or 2 hours after a meal.
(2) Interval requirement: Maintain at least a 2-hour interval before or a 4-hour interval after taking medications or foods containing polyvalent cations.
(3) Method: Swallow the tablet whole; do not chew, crush, or mix with food.
(1) Liver function monitoring
Regularly monitor ALT, AST, and total bilirubin at baseline and during treatment; increase monitoring frequency in patients with liver impairment.
(2) Platelet monitoring
Continue to monitor platelet counts weekly for at least 4 weeks after discontinuation to prevent the risk of thrombosis due to excessive platelet elevation.
